Is Bioidentical HRT FDA-Approved? Compounded vs. FDA-Approved Options Explained

Short answer: yes — FDA-approved bioidentical estradiol, micronized progesterone, and vaginal DHEA already exist. "Bioidentical" is a chemistry claim, not a regulatory one. Compounded bioidentical hormone therapy is not FDA-approved product-by-product, and the 2020 NASEM review found insufficient evidence that it is as safe or as effective as approved options.

Here's some genuinely good news buried in a confusing topic: real, FDA-approved bioidentical hormone options exist, in more forms than most people realize. The confusion mostly comes from "bioidentical" getting used as a marketing term for compounded products, as if the word itself implied something about regulatory status. It doesn't. Here's the actual picture.

FDA-Approved Bioidentical Options Really Do Exist

"Bioidentical" is a molecular description — it means a hormone is chemically identical to what your body produces. It's not a synonym for "compounded," "natural," "safer," or "FDA-approved" — those are separate questions entirely.^[1] ACOG specifically identifies FDA-approved micronized progesterone, estradiol, and DHEA as commercially available bioidentical hormone products.^[1]

• Estradiol — FDA-approved in multiple standardized forms: oral tablets, transdermal patches, gels, sprays, vaginal rings, creams, and tablets/inserts, depending on whether you need systemic treatment (hot flashes) or local treatment (vaginal dryness, pain with sex).^[2]
• Micronized progesterone — FDA-approved as an oral product, generally paired with systemic estrogen in women who have a uterus to protect against endometrial hyperplasia.^[1]
• DHEA— FDA-approved as a vaginal insert specifically for moderate-to-severe pain during sex caused by vulvovaginal atrophy from menopause. This is a genuinely different product from compounded DHEA, which hasn't gone through FDA's individual drug approval process.^[1]

What Compounding Actually Is

Compounded bioidentical hormone therapy (cBHT) is prepared by a pharmacy from a clinician's prescription, often in a patient-specific formulation, dose, combination, or delivery route. Common compounded ingredients include estradiol, estrone, estriol, progesterone, pregnenolone, testosterone, and DHEA.^[3] Compounded preparations aren't reviewed by the FDA before marketing the way an approved drug is. Under Section 503A, qualifying compounders and their patient-specific prescriptions are exempt from FDA's premarket approval process, current Good Manufacturing Practice standards, and labeling requirements.^[3]

Compounding has a real, legitimate role — for patients who can't use an available FDA-approved product because of an inactive ingredient allergy, a needed non-commercial dosage form, or another genuine patient-specific reason. It's not meant to be a routine substitute for a suitable FDA-approved option that already exists.^[1] ACOG's November 2023 Clinical Consensus recommends FDA-approved menopausal hormone therapy over compounded bioidentical therapy, and states compounded products shouldn't be prescribed routinely when an FDA-approved formulation would work.^[1]ACOG also flags that "bioidentical hormone" is sometimes used as a marketing term implying compounded preparations are more natural, safer, or more effective than FDA-approved options — evidence to support that claim doesn't exist.^[1]

What the Major Independent Review Found

In 2020, the National Academies of Sciences, Engineering, and Medicine (NASEM) published an FDA-requested report reviewing cBHT's safety, effectiveness, use, and regulatory oversight.^[4] The findings were fairly direct: most available evidence on cBHT safety and effectiveness came from low-quality sources — anecdotal claims, patient reports, prescriber testimony — rather than rigorous, well-designed controlled clinical studies.^[3]NASEM found insufficient evidence to conclude cBHT is as safe, safer, as effective, or more effective than FDA-approved hormone therapy, and concluded its overall clinical utility for menopause symptoms wasn't supported by sufficient evidence.^[3] The committee also flagged limited federal and state oversight of compounded hormone quality, along with inadequate adverse-event reporting, as real public health concerns.^[3]

There's a practical reason quality control matters here: ACOG cites testing of compounded estradiol/progesterone products that found real variation across pharmacies and even within batches from the same pharmacy — estradiol levels running as much as 26% below the labeled amount, and progesterone as much as 31% above.^[1] FDA-approved medicines go through premarket review covering identity, strength, quality, purity, how the body processes them, labeling, and ongoing safety monitoring — compounded products don't go through that same product-by-product pathway.^[2]

The Testosterone Exception

Worth being clear on this one: there's no FDA-approved testosterone product for managing menopausal symptoms or for cisgender women in the U.S. at all. If a clinician is considering non-FDA-approved or compounded testosterone, that should involve real shared decision-making and an honest conversation about the limits of long-term safety data.^[1]

Pellets: A Delivery Method, Not a Stamp of Approval

Pellet therapy is worth understanding as a delivery method, not a guarantee of bioidentical status or FDA approval. Pellets are small implants placed under the skin that dissolve gradually — unlike a pill, patch, gel, or cream, an inserted pellet isn't designed to be easily stopped or removed if side effects show up or the dose turns out to be too high.^[1] ACOG recommends other preparations over testosterone pellets specifically for menopause-related use, citing limited safety data and the inability to remove them if needed. Reported concerns in the evidence include androgenic effects like acne, increased facial hair, voice changes, mood changes, and abnormal bleeding, with long-term breast and cardiovascular safety still uncertain.^[1]

Setting the Record Straight on the "Difficult to Compound" List

This part gets misreported often enough that it's worth being precise. The FDA's "Difficult to Compound" list refers to specific drug products or categories the FDA determines present real compounding difficulties likely to harm safety or effectiveness — items placed on the final list can't be compounded under Sections 503A or 503B.^[5]The FDA's proposed rule from March 20, 2024 did not add hormones or hormone pellets to this list. It proposed three different categories entirely: oral solid modified-release products using coated systems, liposome drug products, and products made with hot-melt extrusion.^[5]It's not accurate to say the FDA put bioidentical hormone pellets on the Difficult-to-Compound list in 2024.

What actually happened is narrower: NASEM recommended that FDA's Pharmacy Compounding Advisory Committee consider specific hormones — including estradiol, estrone, estradiol cypionate, estriol, DHEA, pregnenolone, progesterone, and certain testosterone products — as candidates for potential review.^[3] NASEM separately recommended the committee consider all cBHT pellet dosage forms as candidates too, citing delivery-mechanism complexity and insufficient compounding guidance.^[3]Both are recommendations for FDA to consider — not a rule, and not a ban on pellet compounding that's actually taken effect.

The Bottom Line

FDA-approved bioidentical options exist across multiple hormones and delivery forms, and they're generally the preferred starting point when they fit what you need. Compounded therapy still has a legitimate role for specific, individual reasons — but it's fair to describe it accurately: custom-compounded, not FDA-approved, and backed by less standardized quality control and less direct clinical evidence than FDA-approved products.^[1]

Worth asking any provider directly whether they're prescribing an FDA-approved product or a compounded preparation, and why — a transparent provider should be able to answer that clearly.

Frequently Asked Questions